Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1981-11-18
pubmed:abstractText
We used cefamandole in the initial treatment of 34 children (10 months to 15 years of age) with suspected bone, joint, or soft tissue infections. The minimal inhibitory concentration of organisms encountered ranged between 0.015 and 2 microgram/ml. At 1 h after intravenous infusion of 25 mg/kg, the mean serum level of cefamandole was 26.2 microgram/ml (range, 8.9 to 47.5 microgram/ml), and at 3 h the level was 1.8 microgram/ml (range, 0.6 to 4.4 microgram/ml), which is above the minimal inhibitory concentration for most of the organisms encountered. However, when the drug was given intravenously every 6 h, the mean level after a 37-mg/kg dose was 0.9 microgram/ml (range, less than 0.5 to 1.9 microgram/ml) at 4 h and, by extrapolation, would have fallen below 0.1 microgram/ml at 6 h. The mean serum half-life was 34 min. Cefamandole appeared to diffuse well into synovial fluid, with joint fluid levels between 5 and 40 microgram/ml. The drug was tolerated well. Cefamandole appears to be a reasonable alternative in the initial treatment of skeletal infections in children, but need to be administered every 4 h to maintain suprainhibitory serum levels between doses.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/7283413-1118208, http://linkedlifedata.com/resource/pubmed/commentcorrection/7283413-113517, http://linkedlifedata.com/resource/pubmed/commentcorrection/7283413-306402, http://linkedlifedata.com/resource/pubmed/commentcorrection/7283413-307939, http://linkedlifedata.com/resource/pubmed/commentcorrection/7283413-349091, http://linkedlifedata.com/resource/pubmed/commentcorrection/7283413-349095, http://linkedlifedata.com/resource/pubmed/commentcorrection/7283413-349097, http://linkedlifedata.com/resource/pubmed/commentcorrection/7283413-356724, http://linkedlifedata.com/resource/pubmed/commentcorrection/7283413-380458, http://linkedlifedata.com/resource/pubmed/commentcorrection/7283413-383011, http://linkedlifedata.com/resource/pubmed/commentcorrection/7283413-418126, http://linkedlifedata.com/resource/pubmed/commentcorrection/7283413-4790616, http://linkedlifedata.com/resource/pubmed/commentcorrection/7283413-4986725, http://linkedlifedata.com/resource/pubmed/commentcorrection/7283413-525985, http://linkedlifedata.com/resource/pubmed/commentcorrection/7283413-570372, http://linkedlifedata.com/resource/pubmed/commentcorrection/7283413-632997, http://linkedlifedata.com/resource/pubmed/commentcorrection/7283413-649995, http://linkedlifedata.com/resource/pubmed/commentcorrection/7283413-649996, http://linkedlifedata.com/resource/pubmed/commentcorrection/7283413-650006, http://linkedlifedata.com/resource/pubmed/commentcorrection/7283413-708009, http://linkedlifedata.com/resource/pubmed/commentcorrection/7283413-7367131
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0066-4804
pubmed:author
pubmed:issnType
Print
pubmed:volume
20
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
21-4
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1981
pubmed:articleTitle
Pharmacology, Safety, and efficacy of cefamandole in childhood infections.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't